KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Accumulated Expenses (2017 - 2025)

Regeneron Pharmaceuticals (REGN) has 12 years of Accumulated Expenses data on record, last reported at $2.9 billion in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 13.82% year-over-year to $2.9 billion; the TTM value through Dec 2025 reached $2.9 billion, up 13.82%, while the annual FY2025 figure was $2.9 billion, 13.82% up from the prior year.
  • Accumulated Expenses reached $2.9 billion in Q4 2025 per REGN's latest filing, down from $3.0 billion in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $3.0 billion in Q3 2025 and bottomed at $1.5 billion in Q1 2021.
  • Average Accumulated Expenses over 5 years is $2.3 billion, with a median of $2.2 billion recorded in 2025.
  • Peak YoY movement for Accumulated Expenses: decreased 12.84% in 2022, then skyrocketed 47.22% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $2.1 billion in 2021, then rose by 0.64% to $2.1 billion in 2022, then rose by 13.68% to $2.4 billion in 2023, then rose by 7.18% to $2.5 billion in 2024, then increased by 13.82% to $2.9 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $2.9 billion in Q4 2025, $3.0 billion in Q3 2025, and $2.5 billion in Q2 2025.